---
title: "Jupiter Neurosciences surges 39% on $100M deal for ALA-002 rights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293353805.md"
description: "JUNS jumps 39% to $0.229 after securing US rights to ALA-002 in a deal worth up to $100M."
datetime: "2026-07-21T14:02:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293353805.md)
  - [en](https://longbridge.com/en/news/293353805.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293353805.md)
generator: "portal-rs"
---

# Jupiter Neurosciences surges 39% on $100M deal for ALA-002 rights

Jupiter Neurosciences（JUNS.US）盘中涨近**39%**，现报**0.229 美元**。

公司与 PharmAla Biotech 签署协议，获得专利非外消旋 MDMA 制剂 ALA-002 的美国独家权利。交易价值高达**1 亿美元**，包括**330 万美元**预付款以及开发、监管和商业里程碑付款。

此次交易使 Jupiter 扩展为双临床阶段 CNS 公司，在其 Phase II 帕金森项目基础上增添 FDA 指定的新化学实体。管理层视此为战略多元化，利用近期加速迷幻疗法的行政命令。

### Related Stocks

- [JUNS.US](https://longbridge.com/en/quote/JUNS.US.md)

## Related News & Research

- [Jupiter Neurosciences Prices $2.0 Million Registered Direct Offering at $6.50 Per Share](https://longbridge.com/en/news/296786477.md)
- [Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | JUNS Stock News](https://longbridge.com/en/news/296638594.md)
- [PharmAla net loss narrows to CAD 499,759 in Q3 FY26; revenue more than doubled to CAD 513,000](https://longbridge.com/en/news/294356612.md)
- [Jupiter Neurosciences FY26 Q2 net loss widens 0.95% to $2.27 million; revenue totals $24,245](https://longbridge.com/en/news/295975039.md)
- [Jupiter Neurosciences Delays Annual 10-K Filing](https://longbridge.com/en/news/281440517.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**